NZ600059A - Antibodies against cd38 for treatment of multiple myeloma - Google Patents
Antibodies against cd38 for treatment of multiple myelomaInfo
- Publication number
- NZ600059A NZ600059A NZ600059A NZ60005906A NZ600059A NZ 600059 A NZ600059 A NZ 600059A NZ 600059 A NZ600059 A NZ 600059A NZ 60005906 A NZ60005906 A NZ 60005906A NZ 600059 A NZ600059 A NZ 600059A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- set forth
- sequence
- human
- light chain
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title 1
- 206010035226 Plasma cell myeloma Diseases 0.000 title 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 102000052645 human CD38 Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
Abstract
Disclosed is an antibody binding to human CD38 encoded by: (i) human light chain and human heavy chain nucleic acids comprising nucleotide sequences in their variable regions as set forth in SEQ ID No:21 and SEQ ID No:26, respectively; or (ii) human light chain and human heavy chain nucleic acids comprising nucleotide sequences in their variable regions, which are conservative sequence modifications of the sequences as set forth in (i). Further disclosed is an antibody binding to human CD38, comprising human light chain and human heavy variable regions, wherein the light chain variable region comprises a VL CDR1 having the sequence as set forth in SEQ ID No:23, a VL CDR2 having the sequence as set forth in SEQ ID No:24 and a VL CDR3 having the sequence as set forth in SEQ ID No:25, and the heavy chain variable region comprises a VH CDR1 having the sequence as set forth in SEQ ID No:28, a VH CDR2 having the sequence as set forth in SEQ ID No:29 and a VH CDR3 having the sequence as set forth in SEQ ID No:30.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ625944A NZ625944A (en) | 2005-03-23 | 2006-03-23 | Antibodies against cd38 for treatment of multiple myeloma |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500429 | 2005-03-23 | ||
| US66757905P | 2005-04-01 | 2005-04-01 | |
| US69616305P | 2005-07-01 | 2005-07-01 | |
| US72856105P | 2005-10-20 | 2005-10-20 | |
| NZ586780A NZ586780A (en) | 2005-03-23 | 2006-03-23 | Antibodies against CD38 for treatment of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ600059A true NZ600059A (en) | 2016-01-29 |
Family
ID=50644285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ600059A NZ600059A (en) | 2005-03-23 | 2006-03-23 | Antibodies against cd38 for treatment of multiple myeloma |
| NZ625944A NZ625944A (en) | 2005-03-23 | 2006-03-23 | Antibodies against cd38 for treatment of multiple myeloma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ625944A NZ625944A (en) | 2005-03-23 | 2006-03-23 | Antibodies against cd38 for treatment of multiple myeloma |
Country Status (11)
| Country | Link |
|---|---|
| KR (1) | KR20140033240A (en) |
| DK (1) | DK1866338T3 (en) |
| ES (2) | ES2606762T3 (en) |
| HU (2) | HUE030783T2 (en) |
| LT (2) | LT2567976T (en) |
| NZ (2) | NZ600059A (en) |
| PL (1) | PL1866338T3 (en) |
| PT (2) | PT2567976T (en) |
| RS (1) | RS55442B1 (en) |
| SG (1) | SG10201610317VA (en) |
| UA (2) | UA98756C2 (en) |
-
2006
- 2006-03-23 ES ES06722861.9T patent/ES2606762T3/en active Active
- 2006-03-23 LT LTEP12178778.2T patent/LT2567976T/en unknown
- 2006-03-23 NZ NZ600059A patent/NZ600059A/en not_active Application Discontinuation
- 2006-03-23 PT PT121787782T patent/PT2567976T/en unknown
- 2006-03-23 PT PT67228619T patent/PT1866338T/en unknown
- 2006-03-23 RS RS20161147A patent/RS55442B1/en unknown
- 2006-03-23 ES ES12178778.2T patent/ES2644982T3/en active Active
- 2006-03-23 DK DK06722861.9T patent/DK1866338T3/en active
- 2006-03-23 PL PL06722861T patent/PL1866338T3/en unknown
- 2006-03-23 UA UAA200711639A patent/UA98756C2/en unknown
- 2006-03-23 NZ NZ625944A patent/NZ625944A/en unknown
- 2006-03-23 UA UAA201204050A patent/UA116520C2/en unknown
- 2006-03-23 KR KR1020147004315A patent/KR20140033240A/en not_active Application Discontinuation
- 2006-03-23 HU HUE06722861A patent/HUE030783T2/en unknown
- 2006-03-23 SG SG10201610317VA patent/SG10201610317VA/en unknown
- 2006-03-23 HU HUE12178778A patent/HUE034962T2/en unknown
- 2006-03-23 LT LTEP06722861.9T patent/LT1866338T/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ625944A (en) | 2016-01-29 |
| ES2606762T3 (en) | 2017-03-27 |
| HUE030783T2 (en) | 2017-06-28 |
| HUE034962T2 (en) | 2018-03-28 |
| RS55442B1 (en) | 2017-04-28 |
| UA98756C2 (en) | 2012-06-25 |
| ES2644982T3 (en) | 2017-12-01 |
| UA116520C2 (en) | 2018-04-10 |
| SG10201610317VA (en) | 2017-02-27 |
| PT1866338T (en) | 2016-12-14 |
| DK1866338T3 (en) | 2017-01-02 |
| LT1866338T (en) | 2017-01-25 |
| LT2567976T (en) | 2017-12-11 |
| KR20140033240A (en) | 2014-03-17 |
| PL1866338T3 (en) | 2017-04-28 |
| PT2567976T (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| TW200720289A (en) | Antibodies against CCR5 and uses thereof | |
| NZ598063A (en) | Gram-positive bacteria specific binding compounds | |
| WO2006055809A3 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| NZ605980A (en) | Anti-fap antibodies and methods of use | |
| RS54452B1 (en) | Compositions and methods for diagnosing and treating cancer | |
| TW200634027A (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| HRP20130922T1 (en) | Fully human antibodies against human 4-1bb (cd137) | |
| FI2155783T4 (en) | Cross-species-specific cd3-epsilon binding domain | |
| NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
| WO2008112004A3 (en) | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF | |
| NZ599405A (en) | Targeted binding agents against b7-h1 | |
| WO2010095031A3 (en) | Humanized antibodies that bind to cd19 and their uses | |
| NZ595235A (en) | Compositions and methods for increasing muscle growth | |
| NZ597466A (en) | Recombinant anti-epidermal growth factor receptor antibody compositions | |
| NZ594275A (en) | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules | |
| RS54393B1 (en) | Human monoclonal antibodies to activin receptor-like kinase-1 | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| WO2007120693A3 (en) | Targeted binding agents directed to upar and uses thereof | |
| WO2008063771A3 (en) | Anti-cd20 antibodies and methods of use | |
| EP2046836A4 (en) | Antibody specifically binding to dr5 and composition for preventing or treating cancers comprising the same | |
| HRP20120759T1 (en) | Cross-species-specific bispecific binders | |
| NZ600005A (en) | Antibodies against human angiopoietin 2 | |
| GEP20074222B (en) | Antibodies to cd40 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AABA | Application abandoned | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 23 MAR 2019 BY WATERMARK PATENT AND TRADE MARKS ATTORNEYS Effective date: 20160504 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2020 BY CPA GLOBAL Effective date: 20190208 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2021 BY CPA GLOBAL Effective date: 20200206 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2022 BY CPA GLOBAL Effective date: 20210204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2023 BY CPA GLOBAL Effective date: 20220204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2024 BY CPA GLOBAL Effective date: 20230210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240208 |